 PITTSBURGH, Oct. 14, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc., Krystal NASDAQ: KRYS, the leader in redosable gene therapies for rare diseases, today announced that it will present pre-clinical pharmacology data on its second genetic pulmonary disease candidate KB408, for the treatment of alpha-1 antitrypsin deficiency AATD, at the upcoming European Society of Gene Cell Therapy ESGCT Virtual Congress held October 19 22, 2021. 